Contracts & Pricing July 24, 2023 340B Contract Pharmacy Restrictions, Legislators on PBMs, and IRA Lawsuits 5 Minute Read Updates on 340B Contract Pharmacy Restrictions from Pharma Manufacturers, Legislators Shift Focus onto PBMs, and IRA Lawsuits.
Specialty Pharmacy July 12, 2023 Thoughts Following Asembia 2023 Part 3: Specialty Lite and Emerging Distribution... 4 Minute Read Channel expert Bill Roth shares information on specialty lite and emerging distribution models.
Contracts & Pricing June 28, 2023 IRA Updates, The Rise of Medical Benefit Contracting, and New CMS... 8 Minute Read Updates on IRA Updates, The Rise of Medical Benefit Contracting, and the New CMS Proposed Rule.
Specialty Pharmacy June 23, 2023 Thoughts Following Asembia 2023 Part 2: Fragmentation and Disruption in the... 3 Minute Read Channel expert Bill Roth explores how we are seeing an unprecedented level of changes and transformation in the industry.
Gross-to-Net June 8, 2023 Monitoring the Gross-to-Net Impacts of WAC Price Increases 2 Minute Read Manufacturers considering taking a WAC price increase this year should be aware of the impact on their GTN line items.
Contracts & Pricing May 31, 2023 Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and... 3 Minute Read Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.
Specialty Pharmacy May 15, 2023 Thoughts Following Asembia 2023 Part 1: Exploring the New Pharmacy Landscape 2 Minute Read Channel expert Bill Roth explores how specialty pharmacy has evolved and their take on the current landscape and insights for pharmaceutical organizations.
Contracts & Pricing April 24, 2023 340B Contract Pharmacy Restrictions, M&A Funding in Biotech & FDA Accelerated... 6 Minute Read Updates on 340B Contract Pharmacy Restriction Updates, M&A and Venture Capital Funding in Biotech, and Stricter Accelerated Approval Criteria Proposed for FDA.
Gross-to-Net April 17, 2023 Why Modernize Your Gross-to-Net? 5 Benefits of Pharma Digital Transformation 2 Minute Read In the current pharma landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. This is primarily because of...
